The Breast Cancer Program is composed of 38 investigators (32 Full and 6 Associate members) from 17 Departments. The Program aims to integrate socio-cultural disparities and population-based research with laboratory-based basic, translational and clinical research programs that can change the state of breast cancer mortality through a synergistic understanding of breast cancer and innovative approaches in treatment. To do so, they have developed the following Specific Aims: 1) Understand the socio-cultural and economic factors that impede diagnosis and care and contribute to disparities in treatment and survival;2) Understand the immunological, micro-environmental, genetic and molecular mechanisms that contribute to the development, invasion, recurrence and metastasis of breast cancer;3) Translate scientific findings to breast cancer development and progression into innovative therapeutics and therapeutic approaches to benefit patients by improving diagnosis and treatment;and 4) Advance the development of clinicians and research scientists working collaboratively to establish novel basic, translational and clinical research areas. To address these aims, six major areas are being developed: 1) Hormonal signaling;2) Invasiveness, metastasis and angiogenesis;3) Immunity/immunological intervention and association with breast cancer;4) Epidemiology;5) Radiobiology and physics research in breast cancer;and 6) Socio-cultural and community based research and programs. Drs. Silvia Formenti and Robert Schneider are the Co-Leaders for this Program. Total funding increased from $9,789,777 to $11,595,777 since the last competitive application. Membership has decreased from 44 to 38. Publications for the period total 275, of which 16.7% are intra-programmatic, 16% are inter-programmatic, and 8.7% are both intra- and inter-programmatic collaborations.

Public Health Relevance

The NYUCI Breast Cancer Research Program integrates socio-cultural disparities and population-based research with laboratory-based research aiming at reducing breast cancer mortality through innovative approaches in prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-34
Application #
8765171
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
34
Fiscal Year
2014
Total Cost
$14,613
Indirect Cost
$5,992
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Wadghiri, Youssef Z; Hoang, Dung Minh; Leporati, Anita et al. (2018) High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease. Sci Rep 8:7687
Khodadadi-Jamayran, Alireza; Akgol-Oksuz, Betul; Afanasyeva, Yelena et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget 9:12868-12878
Nancy, Patrice; Siewiera, Johan; Rizzuto, Gabrielle et al. (2018) H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition. J Clin Invest 128:233-247
Wang, Shiyang; Liechty, Benjamin; Patel, Seema et al. (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138:183-190
Ge, Wenzhen; Clendenen, Tess V; Afanasyeva, Yelena et al. (2018) Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. Int J Cancer 142:2215-2226
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:

Showing the most recent 10 out of 1170 publications